An observational study in Major Depressive Disorder (MDD), sponsored by University of Geneva, Switzerland. Enrolling by invitation at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by University of Geneva, Switzerland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the only one that started in 2026, is one of 5 observational ones, and was the 30th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:
University of Bern · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 21+
University of Bern · Sites in Switzerland
Ages 20–75 · Healthy volunteers
Christoph Nissen · Sites in Switzerland
Ages 30–60 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–65
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 60 across the 25 interventional studies, 190 across the 5 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
University of Geneva, Switzerland is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
University of Geneva, Switzerland has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder, Major with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059234University of BernThe Motor Activity - Subjective Energy (MASE) Project | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Participants will be invited to participate among consecutive patients with treatment-resistant MDD enrolled for psychedelic treatment in the Division of addictology-Department of Psychiatry of the Geneva University hospitals) after receiving approval from the Swiss Federal Office of Public health for compassionate treatment with LSD or psilocybin. Only those receiving LSD or psilocybin for the first time (first treatment cycle) will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Salivary Oxytocin
Measure taken during psychedelic treatment
Time frame: One day
Beck Depression Inventory
Self-reported depressive symptoms
Time frame: 3 months
Cognitive Flexibility Inventory
Self-reported flexibility questionnaire
Time frame: 3 months
Trait anxiety inventory (STAI-T)
Self-reported anxiety symptoms
Time frame: 3 months
Cognitive Emotion Regulation Questionnaire (CERQ)
Self-reported cognitive emotion regulation strategies
Time frame: 3 months
Emotion Regulation Questionnaire
self-reported emotion regulation strategies
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 6 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Geneva, Switzerland